Single dose of trastuzumab kick starts immune response in certain breast cancers

[News]

A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according...

More... (http://www.medicalnewstoday.com/releases/307262.php)